Current Issue


Weight loss through gastric bypass or diet improved insulin sensitivity in patients with type 2 diabetes

Results from this small study suggest that reducing adipose tissue volume, by whatever means, will improve blood glucose control in patients with type 2 diabetes, an accompanying editorial noted.

Recent-onset diabetes, weight loss associated with increased pancreatic cancer risk

Unintentional weight loss and weight loss in those with a body mass index already in the normal range were particularly associated with risk of pancreatic cancer among patients with recent-onset diabetes, a study found.

Adverse events associated with SGLT-2 inhibitors do not appear dose-dependent

In a systematic review and meta-analysis, no difference was seen between high- and low-dose sodium-glucose cotransporter-2 (SGLT-2) inhibitors in overall safety or specific safety outcomes, other than a mild increased risk for adverse events with higher doses of canagliflozin.

MKSAP quiz: Loss of vision in one eye

This month's quiz asks readers to evaluate a patient with total loss of vision in the left eye, a 2-week history of sinus pain and rhinorrhea, and poorly controlled type 1 diabetes.

Spotlight on COVID-19 and new type 1 diabetes

A few case reports suggested a link between SARS-CoV-2 and development of insulin-dependent diabetes, but recent analyses of type 1 diabetes incidence during the pandemic have shown mixed results.

Synopsis covers ADA update on pharmaceutical management of type 2 diabetes

Experts summarized the latest guidance on medication therapy from the American Diabetes Association (ADA) in a recent article.

MELAS syndrome and MIDD unmasked by metformin use

A case report described a patient found to have mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome and maternally inherited diabetes and deafness (MIDD).

ADA conference coverage on kidneys, weight, and insulin switches

The American Diabetes Association (ADA) 2020 Scientific Sessions were held virtually in June and covered in the August ACP Hospitalist and September ACP Internist.

Boxed warning on amputation risk removed from canagliflozin label

Recent studies have found a lower risk of leg and foot amputation than previous studies, which in 2017 had prompted the FDA to add the warning to the sodium-glucose cotransporter-2 inhibitor.